Last 12 months
Inside the activity.
1 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2024 Filed Jul 17, 2024 23:49 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
SaleCommon Stock, $0.01 Par Value | 3,115 | $5.93 | $18,471.95 |
DisclosureSEC source: 0000950170-24-084403 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 857,885 F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established September 5, 2023. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:50 UTC |
Singh Sanjay REVP Technical Operations
|
Tax withholdingCommon Stock, $0.01 Par Value | 5,372 | $5.83 | $31,318.76 |
DisclosureSEC source: 0000950170-24-084408 · ownership.xml · nonDerivative · entry 2 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,487 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:50 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
Tax withholdingCommon Stock, $0.01 Par Value | 1,817 | $5.83 | $10,593.11 |
DisclosureSEC source: 0000950170-24-084407 · ownership.xml · nonDerivative · entry 2 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,256 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:50 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $0.01 Par Value | 11,657 | $5.83 | $67,960.31 |
DisclosureSEC source: 0000950170-24-084406 · ownership.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,147,970 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:49 UTC |
Binder Steven B.EVP Special Projects
|
Tax withholdingCommon Stock, $0.01 Par Value | 11,657 | $5.83 | $67,960.31 |
DisclosureSEC source: 0000950170-24-084405 · ownership.xml · nonDerivative · entry 2 Binder Steven B. · CIK 0001712601 · EVP Special Projects 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,103,696 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:49 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $0.01 Par Value | 47,309 | $5.83 | $275,811.47 |
DisclosureSEC source: 0000950170-24-084404 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,468,921 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:49 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $0.01 Par Value | 12,616 | $5.83 | $73,551.28 |
DisclosureSEC source: 0000950170-24-084403 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 861,000 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 17, 2024 23:50 UTC |
Singh Sanjay REVP Technical Operations
|
GrantCommon Stock, $0.01 Par Value | 3,362 | $3.09 | $10,388.58 |
DisclosureSEC source: 0000950170-24-084408 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,859 F1 · kind: Shares acquired through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 30, 2024 Filed Jul 17, 2024 23:50 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
GrantCommon Stock, $0.01 Par Value | 722 | $3.09 | $2,230.98 |
DisclosureSEC source: 0000950170-24-084407 · ownership.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,073 F1 · kind: Shares acquired through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 30, 2024 Filed Jul 17, 2024 23:50 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock, $0.01 Par Value | 4,689 | $3.09 | $14,489.01 |
DisclosureSEC source: 0000950170-24-084406 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,159,627 F1 · kind: Shares acquired through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 30, 2024 Filed Jul 17, 2024 23:49 UTC |
Binder Steven B.EVP Special Projects
|
GrantCommon Stock, $0.01 Par Value | 800 | $3.09 | $2,472.00 |
DisclosureSEC source: 0000950170-24-084405 · ownership.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · EVP Special Projects 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,115,353 F1 · kind: Shares acquired through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 30, 2024 Filed Jul 17, 2024 23:49 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock, $0.01 Par Value | 5,000 | $3.09 | $15,450.00 |
DisclosureSEC source: 0000950170-24-084404 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,516,230 F1 · kind: Shares acquired through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 24, 2024 Filed May 30, 2024 01:00 UTC |
BLANK BURKHARDEVP Chief Medical Officer
|
Tax withholdingCommon Stock, $0.01 Par Value | 16,151 | $4.78 | $77,201.78 |
DisclosureSEC source: 0000950170-24-066205 · ownership.xml · nonDerivative · entry 1 BLANK BURKHARD · CIK 0001073409 · EVP Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,754 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 21, 2024 Filed May 22, 2024 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
SaleCommon Stock, $0.01 Par Value | 23,537 | $4.66 | $109,682.42 |
DisclosureSEC source: 0000950170-24-063262 · ownership.xml · nonDerivative · entry 4 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 873,616 F3 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established September 5, 2023. Read SEC document |
| May 21, 2024 Filed May 22, 2024 01:00 UTC |
Binder Steven B.EVP Special Projects
|
SaleCommon Stock, $0.01 Par Value | 25,952 | $4.66 | $120,936.32 |
DisclosureSEC source: 0000950170-24-063264 · ownership.xml · nonDerivative · entry 4 Binder Steven B. · CIK 0001712601 · EVP Special Projects 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,114,553 F3 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 18, 2023. Read SEC document |
| May 18, 2024 Filed May 22, 2024 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $0.01 Par Value | 6,916 | $4.59 | $31,744.44 |
DisclosureSEC source: 0000950170-24-063262 · ownership.xml · nonDerivative · entry 3 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 897,153 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2024 Filed May 22, 2024 01:00 UTC |
Binder Steven B.EVP Special Projects
|
Tax withholdingCommon Stock, $0.01 Par Value | 6,162 | $4.59 | $28,283.58 |
DisclosureSEC source: 0000950170-24-063264 · ownership.xml · nonDerivative · entry 3 Binder Steven B. · CIK 0001712601 · EVP Special Projects 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,140,505 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2024 Filed May 22, 2024 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $0.01 Par Value | 26,067 | $4.59 | $119,647.53 |
DisclosureSEC source: 0000950170-24-063261 · ownership.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,511,230 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2024 Filed May 22, 2024 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $0.01 Par Value | 6,130 | $4.59 | $28,136.70 |
DisclosureSEC source: 0000950170-24-063263 · ownership.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,154,938 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 18, 2024 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
OtherCommon Stock, $.01 Par Value | 24,330 | $4.79 | $116,540.70 |
DisclosureSEC source: 0000950170-24-062071 · ownership.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,561,260 F4 · kind: Reporting person transferred 24,330 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree. Read SEC document |
| May 17, 2024 Filed May 18, 2024 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
OtherCommon Stock, $.01 Par Value | 28,670 | $4.32 | $123,854.40 |
DisclosureSEC source: 0000950170-24-062071 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,585,590 F3 · kind: Reporting person transferred 28,670 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $0.01 Par Value | 85,797 | $4.59 | $393,808.23 |
DisclosureSEC source: 0000950170-24-063262 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 904,069 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
GrantCommon Stock, $0.01 Par Value | 77,420 | $4.59 | $355,357.80 |
DisclosureSEC source: 0000950170-24-063262 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 989,866 F1 · kind: A previously reported restricted stock unit award granted on May 18, 2021 vested on May 17, 2024 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 17, 2024 was not less than the closing price on May 17, 2021 and (ii) MannKind's total shareholder return (TSR) over the period from May 18, 2021 to May 17, 2024 was at the 74.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 198% of target, resulting in a total share delivery of 156,420 shares. The acquisition of 79,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 18, 2021. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC |
Binder Steven B.EVP Special Projects
|
Tax withholdingCommon Stock, $0.01 Par Value | 63,720 | $4.59 | $292,474.80 |
DisclosureSEC source: 0000950170-24-063264 · ownership.xml · nonDerivative · entry 2 Binder Steven B. · CIK 0001712601 · EVP Special Projects 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,146,667 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC |
Binder Steven B.EVP Special Projects
|
GrantCommon Stock, $0.01 Par Value | 77,420 | $4.59 | $355,357.80 |
DisclosureSEC source: 0000950170-24-063264 · ownership.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · EVP Special Projects 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,210,387 F1 · kind: A previously reported restricted stock unit award granted on May 18, 2021 vested on May 17, 2024 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 17, 2024 was not less than the closing price on May 17, 2021 and (ii) MannKind's total shareholder return (TSR) over the period from May 18, 2021 to May 17, 2024 was at the 74.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 198% of target, resulting in a total share delivery of 156,420 shares. The acquisition of 79,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 18, 2021. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $0.01 Par Value | 245,443 | $4.59 | $1,126,583.37 |
DisclosureSEC source: 0000950170-24-063261 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,537,297 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock, $0.01 Par Value | 221,480 | $4.59 | $1,016,593.20 |
DisclosureSEC source: 0000950170-24-063261 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,782,740 F1 · kind: A previously reported restricted stock unit award granted on May 18, 2021 vested on May 17, 2024 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 17, 2024 was not less than the closing price on May 17, 2021 and (ii) MannKind's total shareholder return (TSR) over the period from May 18, 2021 to May 17, 2024 was at the 74.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 198% of target, resulting in a total share delivery of 447,480 shares. The acquisition of 226,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 18, 2021. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $0.01 Par Value | 62,056 | $4.59 | $284,837.04 |
DisclosureSEC source: 0000950170-24-063263 · ownership.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161,068 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock, $0.01 Par Value | 77,420 | $4.59 | $355,357.80 |
DisclosureSEC source: 0000950170-24-063263 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,223,124 F1 · kind: A previously reported restricted stock unit award granted on May 18, 2021 vested on May 17, 2024 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 17, 2024 was not less than the closing price on May 17, 2021 and (ii) MannKind's total shareholder return (TSR) over the period from May 18, 2021 to May 17, 2024 was at the 74.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 198% of target, resulting in a total share delivery of 156,420 shares. The acquisition of 79,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 18, 2021. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:36 UTC |
Grancio JenniferDirector
|
GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062088 · ownership.xml · derivative · entry 1 Grancio Jennifer · CIK 0001807888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:35 UTC |
Consiglio Ronald JDirector
|
GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062087 · ownership.xml · derivative · entry 1 CONSIGLIO RONALD J · CIK 0001232088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:34 UTC |
Kay SabrinaDirector
|
GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062086 · ownership.xml · derivative · entry 1 Kay Sabrina · CIK 0001835895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:33 UTC |
Shannon James SamuelDirector
|
GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062085 · ownership.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:32 UTC |
MUNDKUR CHRISTINEDirector
|
GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062084 · ownership.xml · derivative · entry 1 MUNDKUR CHRISTINE · CIK 0001237264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:29 UTC |
HOOPER ANTHONY CDirector
|
GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062082 · ownership.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:31 UTC |
Friedman Michael ADirector
|
GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062083 · ownership.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:29 UTC |
KRESA KENTDirector
|
GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062081 · ownership.xml · derivative · entry 1 KRESA KENT · CIK 0001197571 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantPerformance Restricted Stock Unit · Derivative | 569,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062071 · ownership.xml · derivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 569,000 Underlying: Common Stock, $.01 Par Value · 569,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F5 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F5 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock, $.01 Par Value | 465,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062071 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,614,260 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062070 · ownership.xml · derivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062070 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,145,704 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062069 · ownership.xml · derivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062069 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912,446 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Singh Sanjay REVP Technical Operations
|
GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062066 · ownership.xml · derivative · entry 2 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Singh Sanjay REVP Technical Operations
|
GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062066 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,497 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
BLANK BURKHARDEVP Chief Medical Officer
|
GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062067 · ownership.xml · derivative · entry 2 BLANK BURKHARD · CIK 0001073409 · EVP Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
BLANK BURKHARDEVP Chief Medical Officer
|
GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062067 · ownership.xml · nonDerivative · entry 1 BLANK BURKHARD · CIK 0001073409 · EVP Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 496,905 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Prentiss Christopher BChief Financial Officer
|
GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062064 · ownership.xml · derivative · entry 3 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F4 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Prentiss Christopher BChief Financial Officer
|
GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062064 · ownership.xml · nonDerivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,600 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC |
Prentiss Christopher BChief Financial Officer
|
GrantCommon Stock, $.01 Par Value | 103,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062064 · ownership.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,600 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: 4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. The vesting determination date for this grant is April 22, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.